Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Molecular Pharmacology
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Molecular Pharmacology

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit molpharm on Facebook
  • Follow molpharm on Twitter
  • Follow molpharm on LinkedIn

Index by author

September 01, 1988; Volume 34,Issue 3
  • A
  • B
  • C
  • D
  • E
  • F
  • G
  • H
  • I
  • J
  • K
  • L
  • M
  • N
  • O
  • P
  • Q
  • R
  • S
  • T
  • U
  • V
  • W
  • X
  • Y
  • Z

A

  1. Adamik, R

    1. You have access
      Mechanism of enhanced sensitivity to bradykinin in pertussis toxin-treated fibroblasts: toxin increases bradykinin-stimulated prostaglandin formation.
      J Moss, B E Hom, E L Hewlett, S C Tsai, R Adamik, J L Halpern, S R Price and V C Manganiello
      Molecular Pharmacology September 1988, 34 (3) 279-285;
  2. Antkiewicz-Michaluk, L

    1. You have access
      Molecular characterization and mitochondrial density of a recognition site for peripheral-type benzodiazepine ligands.
      L Antkiewicz-Michaluk, A Guidotti and K E Krueger
      Molecular Pharmacology September 1988, 34 (3) 272-278;
  3. Artymyshyn, R P

    1. You have access
      Antibodies to a synthetic peptide can be used to distinguish between muscarinic acetylcholine receptor binding sites in brain and heart.
      G R Luthin, J Harkness, R P Artymyshyn and B B Wolfe
      Molecular Pharmacology September 1988, 34 (3) 327-333;

B

  1. Bahouth, S W

    1. You have access
      Subclassification of beta-adrenergic receptors of rat fat cells: a re-evaluation.
      S W Bahouth and C C Malbon
      Molecular Pharmacology September 1988, 34 (3) 318-326;
  2. Bonhaus, D W

    1. You have access
      N-methyl-D-aspartate receptor regulation of uncompetitive antagonist binding in rat brain membranes: kinetic analysis.
      D W Bonhaus and J O McNamara
      Molecular Pharmacology September 1988, 34 (3) 250-255;
  3. Borden, L A

    1. You have access
      Mechanism of gamma-aminobutyric acid/benzodiazepine receptor turnover in neuronal cells: evidence for nonlysosomal degradation.
      L A Borden and D H Farb
      Molecular Pharmacology September 1988, 34 (3) 354-362;

C

  1. Camerman, A

    1. You have access
      Structure-activity studies of morphine fragments. I. 4-alkyl-4-(m-hydroxy-phenyl)-piperidines.
      G H Loew, J A Lawson, E T Uyeno, L Toll, G Frenking, W Polgar, L Y Ma, N Camerman and A Camerman
      Molecular Pharmacology September 1988, 34 (3) 363-376;
  2. Camerman, N

    1. You have access
      Structure-activity studies of morphine fragments. I. 4-alkyl-4-(m-hydroxy-phenyl)-piperidines.
      G H Loew, J A Lawson, E T Uyeno, L Toll, G Frenking, W Polgar, L Y Ma, N Camerman and A Camerman
      Molecular Pharmacology September 1988, 34 (3) 363-376;
  3. Chen, J

    1. You have access
      Dihydropyridine Bay K 8644 activates T lymphocyte calcium-permeable channels.
      W Young, J Chen, F Jung and P Gardner
      Molecular Pharmacology September 1988, 34 (3) 239-244;
  4. Clark, J A

    1. You have access
      Opiate binding in calf thalamic membranes: a selective mu 1 binding assay.
      J A Clark, R Houghten and G W Pasternak
      Molecular Pharmacology September 1988, 34 (3) 308-317;
  5. Cowlen, M S

    1. You have access
      Evidence for alpha 1-adrenergic receptor internalization in DDT1 MF-2 cells following exposure to agonists plus protein kinase C activators.
      M S Cowlen and M L Toews
      Molecular Pharmacology September 1988, 34 (3) 340-346;

D

  1. Dekant, W

    1. You have access
      Metabolism and excretion of S-conjugates derived from hexachlorobutadiene in the isolated perfused rat kidney.
      D Schrenk, W Dekant and D Henschler
      Molecular Pharmacology September 1988, 34 (3) 407-412;
  2. Dingledine, R

    1. You have access
      Excitatory amino acid receptors expressed in Xenopus oocytes: agonist pharmacology.
      T A Verdoorn and R Dingledine
      Molecular Pharmacology September 1988, 34 (3) 298-307;

E

  1. Edmondson, D E

    1. You have access
      Effect of hypoxia on tert-butylhydroperoxide-induced oxidative injury in hepatocytes.
      D L Tribble, D P Jones and D E Edmondson
      Molecular Pharmacology September 1988, 34 (3) 413-420;
  2. Everson, R B

    1. You have access
      Smoking-related alterations in epidermal growth factor and insulin receptors in human placenta.
      S L Wang, G W Lucier, R B Everson, G I Sunahara and K T Shiverick
      Molecular Pharmacology September 1988, 34 (3) 265-271;

F

  1. Farb, D H

    1. You have access
      Mechanism of gamma-aminobutyric acid/benzodiazepine receptor turnover in neuronal cells: evidence for nonlysosomal degradation.
      L A Borden and D H Farb
      Molecular Pharmacology September 1988, 34 (3) 354-362;
  2. Fisher, J M

    1. You have access
      Evidence for a copper:S-(methylthio)-L-homocysteine complex as a glutamine antagonist of cytidine triphosphate synthesis in L1210 murine leukemia cells.
      M Rabinovitz and J M Fisher
      Molecular Pharmacology September 1988, 34 (3) 401-406;
  3. Frenking, G

    1. You have access
      Structure-activity studies of morphine fragments. I. 4-alkyl-4-(m-hydroxy-phenyl)-piperidines.
      G H Loew, J A Lawson, E T Uyeno, L Toll, G Frenking, W Polgar, L Y Ma, N Camerman and A Camerman
      Molecular Pharmacology September 1988, 34 (3) 363-376;
  4. Freytag, S

    1. You have access
      Inhibition of glucokinase by alloxan through interaction with SH groups in the sugar-binding site of the enzyme.
      S Lenzen, S Freytag and U Panten
      Molecular Pharmacology September 1988, 34 (3) 395-400;

G

  1. Gardner, P

    1. You have access
      Dihydropyridine Bay K 8644 activates T lymphocyte calcium-permeable channels.
      W Young, J Chen, F Jung and P Gardner
      Molecular Pharmacology September 1988, 34 (3) 239-244;
  2. Goldman, D W

    1. You have access
      Conversion of 5-hydroperoxyeicosatetraenoic acid into leukotriene B4 by rat hepatocytes: a novel cellular source for leukotriene B4.
      J Gut, D W Goldman and J R Trudell
      Molecular Pharmacology September 1988, 34 (3) 256-264;
  3. Guidotti, A

    1. You have access
      Molecular characterization and mitochondrial density of a recognition site for peripheral-type benzodiazepine ligands.
      L Antkiewicz-Michaluk, A Guidotti and K E Krueger
      Molecular Pharmacology September 1988, 34 (3) 272-278;
  4. Gut, J

    1. You have access
      Conversion of 5-hydroperoxyeicosatetraenoic acid into leukotriene B4 by rat hepatocytes: a novel cellular source for leukotriene B4.
      J Gut, D W Goldman and J R Trudell
      Molecular Pharmacology September 1988, 34 (3) 256-264;

H

  1. Halpern, J L

    1. You have access
      Mechanism of enhanced sensitivity to bradykinin in pertussis toxin-treated fibroblasts: toxin increases bradykinin-stimulated prostaglandin formation.
      J Moss, B E Hom, E L Hewlett, S C Tsai, R Adamik, J L Halpern, S R Price and V C Manganiello
      Molecular Pharmacology September 1988, 34 (3) 279-285;
  2. Harkness, J

    1. You have access
      Antibodies to a synthetic peptide can be used to distinguish between muscarinic acetylcholine receptor binding sites in brain and heart.
      G R Luthin, J Harkness, R P Artymyshyn and B B Wolfe
      Molecular Pharmacology September 1988, 34 (3) 327-333;
  3. Henschler, D

    1. You have access
      Metabolism and excretion of S-conjugates derived from hexachlorobutadiene in the isolated perfused rat kidney.
      D Schrenk, W Dekant and D Henschler
      Molecular Pharmacology September 1988, 34 (3) 407-412;
  4. Hess, M L

    1. You have access
      The effect of oxygen free radicals on calcium permeability and calcium loading at steady state in cardiac sarcoplasmic reticulum.
      E Okabe, C Odajima, R Taga, R C Kukreja, M L Hess and H Ito
      Molecular Pharmacology September 1988, 34 (3) 388-394;
  5. Hewlett, E L

    1. You have access
      Mechanism of enhanced sensitivity to bradykinin in pertussis toxin-treated fibroblasts: toxin increases bradykinin-stimulated prostaglandin formation.
      J Moss, B E Hom, E L Hewlett, S C Tsai, R Adamik, J L Halpern, S R Price and V C Manganiello
      Molecular Pharmacology September 1988, 34 (3) 279-285;
  6. Hom, B E

    1. You have access
      Mechanism of enhanced sensitivity to bradykinin in pertussis toxin-treated fibroblasts: toxin increases bradykinin-stimulated prostaglandin formation.
      J Moss, B E Hom, E L Hewlett, S C Tsai, R Adamik, J L Halpern, S R Price and V C Manganiello
      Molecular Pharmacology September 1988, 34 (3) 279-285;
  7. Houghten, R

    1. You have access
      Opiate binding in calf thalamic membranes: a selective mu 1 binding assay.
      J A Clark, R Houghten and G W Pasternak
      Molecular Pharmacology September 1988, 34 (3) 308-317;

I

  1. In, Y

    1. You have access
      Structure-activity relationship of aldose reductase inhibitors based on X-ray crystal structures of oxazolecarbamate derivatives.
      T Ishida, Y In, H Ohishi, D Yamamoto, M Inoue, C Tanaka, Y Ueno, Y Ohmomo, N Kanda and A Tanaka
      Molecular Pharmacology September 1988, 34 (3) 377-387;
  2. Inoue, M

    1. You have access
      Structure-activity relationship of aldose reductase inhibitors based on X-ray crystal structures of oxazolecarbamate derivatives.
      T Ishida, Y In, H Ohishi, D Yamamoto, M Inoue, C Tanaka, Y Ueno, Y Ohmomo, N Kanda and A Tanaka
      Molecular Pharmacology September 1988, 34 (3) 377-387;
  3. Ishida, T

    1. You have access
      Structure-activity relationship of aldose reductase inhibitors based on X-ray crystal structures of oxazolecarbamate derivatives.
      T Ishida, Y In, H Ohishi, D Yamamoto, M Inoue, C Tanaka, Y Ueno, Y Ohmomo, N Kanda and A Tanaka
      Molecular Pharmacology September 1988, 34 (3) 377-387;
  4. Ito, H

    1. You have access
      The effect of oxygen free radicals on calcium permeability and calcium loading at steady state in cardiac sarcoplasmic reticulum.
      E Okabe, C Odajima, R Taga, R C Kukreja, M L Hess and H Ito
      Molecular Pharmacology September 1988, 34 (3) 388-394;

J

  1. Jones, D P

    1. You have access
      Effect of hypoxia on tert-butylhydroperoxide-induced oxidative injury in hepatocytes.
      D L Tribble, D P Jones and D E Edmondson
      Molecular Pharmacology September 1988, 34 (3) 413-420;
  2. Juliano, R L

    1. You have access
      Interactions of liposome-incorporated amphotericin B with kidney epithelial cell cultures.
      H J Krause and R L Juliano
      Molecular Pharmacology September 1988, 34 (3) 286-297;
  3. Jung, F

    1. You have access
      Dihydropyridine Bay K 8644 activates T lymphocyte calcium-permeable channels.
      W Young, J Chen, F Jung and P Gardner
      Molecular Pharmacology September 1988, 34 (3) 239-244;

K

  1. Kanda, N

    1. You have access
      Structure-activity relationship of aldose reductase inhibitors based on X-ray crystal structures of oxazolecarbamate derivatives.
      T Ishida, Y In, H Ohishi, D Yamamoto, M Inoue, C Tanaka, Y Ueno, Y Ohmomo, N Kanda and A Tanaka
      Molecular Pharmacology September 1988, 34 (3) 377-387;
  2. Karlish, S J

    1. You have access
      Do canrenone and 6,7-dihydroxylated derivatives compete with ouabain at the same site on Na,K-ATPase?
      D M Tal and S J Karlish
      Molecular Pharmacology September 1988, 34 (3) 245-249;
  3. Krause, H J

    1. You have access
      Interactions of liposome-incorporated amphotericin B with kidney epithelial cell cultures.
      H J Krause and R L Juliano
      Molecular Pharmacology September 1988, 34 (3) 286-297;
  4. Krueger, K E

    1. You have access
      Molecular characterization and mitochondrial density of a recognition site for peripheral-type benzodiazepine ligands.
      L Antkiewicz-Michaluk, A Guidotti and K E Krueger
      Molecular Pharmacology September 1988, 34 (3) 272-278;
  5. Kukreja, R C

    1. You have access
      The effect of oxygen free radicals on calcium permeability and calcium loading at steady state in cardiac sarcoplasmic reticulum.
      E Okabe, C Odajima, R Taga, R C Kukreja, M L Hess and H Ito
      Molecular Pharmacology September 1988, 34 (3) 388-394;

L

  1. Lawson, J A

    1. You have access
      Structure-activity studies of morphine fragments. I. 4-alkyl-4-(m-hydroxy-phenyl)-piperidines.
      G H Loew, J A Lawson, E T Uyeno, L Toll, G Frenking, W Polgar, L Y Ma, N Camerman and A Camerman
      Molecular Pharmacology September 1988, 34 (3) 363-376;
  2. Leid, M

    1. You have access
      Characterization of agonist radioligand interactions with porcine atrial A1 adenosine receptors.
      M Leid, M I Schimerlik and T F Murray
      Molecular Pharmacology September 1988, 34 (3) 334-339;
  3. Lenzen, S

    1. You have access
      Inhibition of glucokinase by alloxan through interaction with SH groups in the sugar-binding site of the enzyme.
      S Lenzen, S Freytag and U Panten
      Molecular Pharmacology September 1988, 34 (3) 395-400;
  4. Loew, G H

    1. You have access
      Structure-activity studies of morphine fragments. I. 4-alkyl-4-(m-hydroxy-phenyl)-piperidines.
      G H Loew, J A Lawson, E T Uyeno, L Toll, G Frenking, W Polgar, L Y Ma, N Camerman and A Camerman
      Molecular Pharmacology September 1988, 34 (3) 363-376;
  5. Lucier, G W

    1. You have access
      Smoking-related alterations in epidermal growth factor and insulin receptors in human placenta.
      S L Wang, G W Lucier, R B Everson, G I Sunahara and K T Shiverick
      Molecular Pharmacology September 1988, 34 (3) 265-271;
  6. Luthin, G R

    1. You have access
      Antibodies to a synthetic peptide can be used to distinguish between muscarinic acetylcholine receptor binding sites in brain and heart.
      G R Luthin, J Harkness, R P Artymyshyn and B B Wolfe
      Molecular Pharmacology September 1988, 34 (3) 327-333;

M

  1. Ma, L Y

    1. You have access
      Structure-activity studies of morphine fragments. I. 4-alkyl-4-(m-hydroxy-phenyl)-piperidines.
      G H Loew, J A Lawson, E T Uyeno, L Toll, G Frenking, W Polgar, L Y Ma, N Camerman and A Camerman
      Molecular Pharmacology September 1988, 34 (3) 363-376;
  2. Malbon, C C

    1. You have access
      Subclassification of beta-adrenergic receptors of rat fat cells: a re-evaluation.
      S W Bahouth and C C Malbon
      Molecular Pharmacology September 1988, 34 (3) 318-326;
  3. Manganiello, V C

    1. You have access
      Mechanism of enhanced sensitivity to bradykinin in pertussis toxin-treated fibroblasts: toxin increases bradykinin-stimulated prostaglandin formation.
      J Moss, B E Hom, E L Hewlett, S C Tsai, R Adamik, J L Halpern, S R Price and V C Manganiello
      Molecular Pharmacology September 1988, 34 (3) 279-285;
  4. McNamara, J O

    1. You have access
      N-methyl-D-aspartate receptor regulation of uncompetitive antagonist binding in rat brain membranes: kinetic analysis.
      D W Bonhaus and J O McNamara
      Molecular Pharmacology September 1988, 34 (3) 250-255;
  5. Moss, J

    1. You have access
      Mechanism of enhanced sensitivity to bradykinin in pertussis toxin-treated fibroblasts: toxin increases bradykinin-stimulated prostaglandin formation.
      J Moss, B E Hom, E L Hewlett, S C Tsai, R Adamik, J L Halpern, S R Price and V C Manganiello
      Molecular Pharmacology September 1988, 34 (3) 279-285;
  6. Motulsky, H J

    1. You have access
      The potency and kinetics of the beta-adrenergic receptors on human neutrophils.
      H Mueller, H J Motulsky and L A Sklar
      Molecular Pharmacology September 1988, 34 (3) 347-353;
  7. Mueller, H

    1. You have access
      The potency and kinetics of the beta-adrenergic receptors on human neutrophils.
      H Mueller, H J Motulsky and L A Sklar
      Molecular Pharmacology September 1988, 34 (3) 347-353;
  8. Murray, T F

    1. You have access
      Characterization of agonist radioligand interactions with porcine atrial A1 adenosine receptors.
      M Leid, M I Schimerlik and T F Murray
      Molecular Pharmacology September 1988, 34 (3) 334-339;

O

  1. Odajima, C

    1. You have access
      The effect of oxygen free radicals on calcium permeability and calcium loading at steady state in cardiac sarcoplasmic reticulum.
      E Okabe, C Odajima, R Taga, R C Kukreja, M L Hess and H Ito
      Molecular Pharmacology September 1988, 34 (3) 388-394;
  2. Ohishi, H

    1. You have access
      Structure-activity relationship of aldose reductase inhibitors based on X-ray crystal structures of oxazolecarbamate derivatives.
      T Ishida, Y In, H Ohishi, D Yamamoto, M Inoue, C Tanaka, Y Ueno, Y Ohmomo, N Kanda and A Tanaka
      Molecular Pharmacology September 1988, 34 (3) 377-387;
  3. Ohmomo, Y

    1. You have access
      Structure-activity relationship of aldose reductase inhibitors based on X-ray crystal structures of oxazolecarbamate derivatives.
      T Ishida, Y In, H Ohishi, D Yamamoto, M Inoue, C Tanaka, Y Ueno, Y Ohmomo, N Kanda and A Tanaka
      Molecular Pharmacology September 1988, 34 (3) 377-387;
  4. Okabe, E

    1. You have access
      The effect of oxygen free radicals on calcium permeability and calcium loading at steady state in cardiac sarcoplasmic reticulum.
      E Okabe, C Odajima, R Taga, R C Kukreja, M L Hess and H Ito
      Molecular Pharmacology September 1988, 34 (3) 388-394;

P

  1. Panten, U

    1. You have access
      Inhibition of glucokinase by alloxan through interaction with SH groups in the sugar-binding site of the enzyme.
      S Lenzen, S Freytag and U Panten
      Molecular Pharmacology September 1988, 34 (3) 395-400;
  2. Pasternak, G W

    1. You have access
      Opiate binding in calf thalamic membranes: a selective mu 1 binding assay.
      J A Clark, R Houghten and G W Pasternak
      Molecular Pharmacology September 1988, 34 (3) 308-317;
  3. Polgar, W

    1. You have access
      Structure-activity studies of morphine fragments. I. 4-alkyl-4-(m-hydroxy-phenyl)-piperidines.
      G H Loew, J A Lawson, E T Uyeno, L Toll, G Frenking, W Polgar, L Y Ma, N Camerman and A Camerman
      Molecular Pharmacology September 1988, 34 (3) 363-376;
  4. Price, S R

    1. You have access
      Mechanism of enhanced sensitivity to bradykinin in pertussis toxin-treated fibroblasts: toxin increases bradykinin-stimulated prostaglandin formation.
      J Moss, B E Hom, E L Hewlett, S C Tsai, R Adamik, J L Halpern, S R Price and V C Manganiello
      Molecular Pharmacology September 1988, 34 (3) 279-285;

R

  1. Rabinovitz, M

    1. You have access
      Evidence for a copper:S-(methylthio)-L-homocysteine complex as a glutamine antagonist of cytidine triphosphate synthesis in L1210 murine leukemia cells.
      M Rabinovitz and J M Fisher
      Molecular Pharmacology September 1988, 34 (3) 401-406;

S

  1. Schimerlik, M I

    1. You have access
      Characterization of agonist radioligand interactions with porcine atrial A1 adenosine receptors.
      M Leid, M I Schimerlik and T F Murray
      Molecular Pharmacology September 1988, 34 (3) 334-339;
  2. Schrenk, D

    1. You have access
      Metabolism and excretion of S-conjugates derived from hexachlorobutadiene in the isolated perfused rat kidney.
      D Schrenk, W Dekant and D Henschler
      Molecular Pharmacology September 1988, 34 (3) 407-412;
  3. Shiverick, K T

    1. You have access
      Smoking-related alterations in epidermal growth factor and insulin receptors in human placenta.
      S L Wang, G W Lucier, R B Everson, G I Sunahara and K T Shiverick
      Molecular Pharmacology September 1988, 34 (3) 265-271;
  4. Sklar, L A

    1. You have access
      The potency and kinetics of the beta-adrenergic receptors on human neutrophils.
      H Mueller, H J Motulsky and L A Sklar
      Molecular Pharmacology September 1988, 34 (3) 347-353;
  5. Sunahara, G I

    1. You have access
      Smoking-related alterations in epidermal growth factor and insulin receptors in human placenta.
      S L Wang, G W Lucier, R B Everson, G I Sunahara and K T Shiverick
      Molecular Pharmacology September 1988, 34 (3) 265-271;

T

  1. Taga, R

    1. You have access
      The effect of oxygen free radicals on calcium permeability and calcium loading at steady state in cardiac sarcoplasmic reticulum.
      E Okabe, C Odajima, R Taga, R C Kukreja, M L Hess and H Ito
      Molecular Pharmacology September 1988, 34 (3) 388-394;
  2. Tal, D M

    1. You have access
      Do canrenone and 6,7-dihydroxylated derivatives compete with ouabain at the same site on Na,K-ATPase?
      D M Tal and S J Karlish
      Molecular Pharmacology September 1988, 34 (3) 245-249;
  3. Tanaka, A

    1. You have access
      Structure-activity relationship of aldose reductase inhibitors based on X-ray crystal structures of oxazolecarbamate derivatives.
      T Ishida, Y In, H Ohishi, D Yamamoto, M Inoue, C Tanaka, Y Ueno, Y Ohmomo, N Kanda and A Tanaka
      Molecular Pharmacology September 1988, 34 (3) 377-387;
  4. Tanaka, C

    1. You have access
      Structure-activity relationship of aldose reductase inhibitors based on X-ray crystal structures of oxazolecarbamate derivatives.
      T Ishida, Y In, H Ohishi, D Yamamoto, M Inoue, C Tanaka, Y Ueno, Y Ohmomo, N Kanda and A Tanaka
      Molecular Pharmacology September 1988, 34 (3) 377-387;
  5. Toews, M L

    1. You have access
      Evidence for alpha 1-adrenergic receptor internalization in DDT1 MF-2 cells following exposure to agonists plus protein kinase C activators.
      M S Cowlen and M L Toews
      Molecular Pharmacology September 1988, 34 (3) 340-346;
  6. Toll, L

    1. You have access
      Structure-activity studies of morphine fragments. I. 4-alkyl-4-(m-hydroxy-phenyl)-piperidines.
      G H Loew, J A Lawson, E T Uyeno, L Toll, G Frenking, W Polgar, L Y Ma, N Camerman and A Camerman
      Molecular Pharmacology September 1988, 34 (3) 363-376;
  7. Tribble, D L

    1. You have access
      Effect of hypoxia on tert-butylhydroperoxide-induced oxidative injury in hepatocytes.
      D L Tribble, D P Jones and D E Edmondson
      Molecular Pharmacology September 1988, 34 (3) 413-420;
  8. Trudell, J R

    1. You have access
      Conversion of 5-hydroperoxyeicosatetraenoic acid into leukotriene B4 by rat hepatocytes: a novel cellular source for leukotriene B4.
      J Gut, D W Goldman and J R Trudell
      Molecular Pharmacology September 1988, 34 (3) 256-264;
  9. Tsai, S C

    1. You have access
      Mechanism of enhanced sensitivity to bradykinin in pertussis toxin-treated fibroblasts: toxin increases bradykinin-stimulated prostaglandin formation.
      J Moss, B E Hom, E L Hewlett, S C Tsai, R Adamik, J L Halpern, S R Price and V C Manganiello
      Molecular Pharmacology September 1988, 34 (3) 279-285;

U

  1. Ueno, Y

    1. You have access
      Structure-activity relationship of aldose reductase inhibitors based on X-ray crystal structures of oxazolecarbamate derivatives.
      T Ishida, Y In, H Ohishi, D Yamamoto, M Inoue, C Tanaka, Y Ueno, Y Ohmomo, N Kanda and A Tanaka
      Molecular Pharmacology September 1988, 34 (3) 377-387;
  2. Uyeno, E T

    1. You have access
      Structure-activity studies of morphine fragments. I. 4-alkyl-4-(m-hydroxy-phenyl)-piperidines.
      G H Loew, J A Lawson, E T Uyeno, L Toll, G Frenking, W Polgar, L Y Ma, N Camerman and A Camerman
      Molecular Pharmacology September 1988, 34 (3) 363-376;

V

  1. Verdoorn, T A

    1. You have access
      Excitatory amino acid receptors expressed in Xenopus oocytes: agonist pharmacology.
      T A Verdoorn and R Dingledine
      Molecular Pharmacology September 1988, 34 (3) 298-307;

W

  1. Wang, S L

    1. You have access
      Smoking-related alterations in epidermal growth factor and insulin receptors in human placenta.
      S L Wang, G W Lucier, R B Everson, G I Sunahara and K T Shiverick
      Molecular Pharmacology September 1988, 34 (3) 265-271;
  2. Wolfe, B B

    1. You have access
      Antibodies to a synthetic peptide can be used to distinguish between muscarinic acetylcholine receptor binding sites in brain and heart.
      G R Luthin, J Harkness, R P Artymyshyn and B B Wolfe
      Molecular Pharmacology September 1988, 34 (3) 327-333;

Y

  1. Yamamoto, D

    1. You have access
      Structure-activity relationship of aldose reductase inhibitors based on X-ray crystal structures of oxazolecarbamate derivatives.
      T Ishida, Y In, H Ohishi, D Yamamoto, M Inoue, C Tanaka, Y Ueno, Y Ohmomo, N Kanda and A Tanaka
      Molecular Pharmacology September 1988, 34 (3) 377-387;
  2. Young, W

    1. You have access
      Dihydropyridine Bay K 8644 activates T lymphocyte calcium-permeable channels.
      W Young, J Chen, F Jung and P Gardner
      Molecular Pharmacology September 1988, 34 (3) 239-244;
Back to top
PreviousNext

In this issue

Molecular Pharmacology
Vol. 34, Issue 3
1 Sep 1988
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Back Matter (PDF)
  • Editorial Board (PDF)
  • Front Matter (PDF)
Sign up for alerts
  • Most Cited
  • Most Read
Loading
  • SB-431542 Is a Potent and Specific Inhibitor of Transforming Growth Factor-β Superfamily Type I Activin Receptor-Like Kinase (ALK) Receptors ALK4, ALK5, and ALK7
  • The G-Protein-Coupled Receptors in the Human Genome Form Five Main Families. Phylogenetic Analysis, Paralogon Groups, and Fingerprints
  • Pharmacological Properties of Y-27632, a Specific Inhibitor of Rho-Associated Kinases
  • Pharmacological characterization of five cloned voltage-gated K+ channels, types Kv1.1, 1.2, 1.3, 1.5, and 3.1, stably expressed in mammalian cell lines.
  • The Orphan Human Pregnane X Receptor Mediates the Transcriptional Activation of CYP3A4 by Rifampicin through a Distal Enhancer Module
More...
Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About Molecular Pharmacology
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Journal of Pharmacology and Experimental Therapeutics
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0111 (Online)

Copyright © 2023 by the American Society for Pharmacology and Experimental Therapeutics